2021
The Government’s Involvement in Prenatal Drug Testing May Be Toxic
Nguemeni Tiako MJ, Sweeney L. The Government’s Involvement in Prenatal Drug Testing May Be Toxic. Maternal And Child Health Journal 2021, 26: 761-763. PMID: 33392931, DOI: 10.1007/s10995-020-03110-2.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersPregnant patientsSubstance useNon-pregnant peoplePrenatal drug testingNeonatal abstinence syndromePublic health scaleEvidence-based carePrenatal substance usePatient-provider relationshipReportable offenseWhite patientsBlack patientsAbstinence syndromeObstetric careChronic illnessGreater oddsHealthcare providersPatientsPregnant peopleHealthcare professionalsGreater riskRacial disparitiesDrug testing
2020
Geographic Distribution of Medicaid-Claimant OB-GYNs Approved to Prescribe Buprenorphine for Opioid Use Disorder [15E]
Nguemeni Tiako M, Culhane J, Meisel Z. Geographic Distribution of Medicaid-Claimant OB-GYNs Approved to Prescribe Buprenorphine for Opioid Use Disorder [15E]. Obstetrics And Gynecology 2020, 135: 53s-53s. DOI: 10.1097/01.aog.0000663556.94003.be.Peer-Reviewed Original ResearchOpioid use disorderNeonatal abstinence syndromeOb-gynsUse disordersIncidence of NASHighest opioid overdose death ratesGuideline-recommended treatmentMaternal-fetal outcomesShorter hospital stayOpioid overdose death ratesU.S. opioid epidemicOverdose death ratesRural-Urban Continuum CodesUtero buprenorphine exposureNAS symptomsPrescribe BuprenorphinePrescribing barriersHospital stayBuprenorphine exposureMedicaid insuranceAbstinence syndromeOpioid epidemicBuprenorphine accessEffective treatmentHigh incidence